| |
Japan may suggest smaller whale catch after ICJ blow Monday, Mar 31, 2014 08:46 PM PDT | Top |
Protest-hit China city says no plant without public support Monday, Mar 31, 2014 08:33 PM PDT A city in southern China which has been the site of violent protests against a proposed chemical plant said it will not go ahead with the project if a majority of residents object to it, as authorities seek to head off more unrest. Photos posted on Weibo, China's Twitter-like microblog service, have showed hundreds of demonstrators marching along the streets over the past two days, an overturned car in flames and protesters laying bloodied on the road. "If the majority of people are against it, the city government won't make a decision contrary to public opinion," it said. Maoming residents have been protesting the production of paraxylene, a chemical used to make fabrics and plastic bottles at a plant run by the local government and state-owned Sinopec Corp, China's biggest refiner. Full Story | Top |
Green Investment Bank buys wind farm stakes from DONG, RWE Monday, Mar 31, 2014 08:25 PM PDT | Top |
Government picks Babcock and Fluor for 7 billion pounds nuclear decommissioning Monday, Mar 31, 2014 08:15 PM PDT By Li-mei Hoang and Brenda Goh LONDON (Reuters) - Britain awarded a 7-billion-pound contract to manage the decommissioning of nearly half its nuclear sites to engineering contractors Babcock and U.S. group Fluor in one of the largest government contracts ever put out to tender. The 14-year deal covers some of Britain's oldest nuclear power sites include Hinkley, Sizewell and Dungeness. Britain has moved to outsource large swathes of its public sector services over the last 30 years, a practice which has been heavily criticised in recent months after contractors such as G4S and Serco were found to have overcharged the government on contracts. Full Story | Top |
Russian prime minister angers Ukraine by visiting Crimea Monday, Mar 31, 2014 05:07 PM PDT | Top |
Scale of Guinea's Ebola epidemic unprecedented: aid agency Monday, Mar 31, 2014 03:55 PM PDT By Saliou Samb CONAKRY (Reuters) - Guinea faces an Ebola epidemic on an unprecedented scale as it battles to contain confirmed cases now scattered across several locations that are far apart, medical charity Medecins Sans Frontieres said on Monday. The warning from an organization with experience of tackling Ebola in Central Africa comes after Guinea's president appealed for calm as the number of deaths linked to an outbreak on the border with Liberia and Sierra Leone hit 80. The outbreak of one of the world's most lethal infectious diseases has spooked a number of governments with weak health systems, prompting Senegal to close its border with Guinea and other neighbors to restrict travel and cross-border exchanges. Figures released overnight by Guinea's health ministry showed that there had been 78 deaths from 122 cases of suspected Ebola since January, up from 70. Full Story | Top |
Sherritt files proxy, urges rejection of dissident's nominees Monday, Mar 31, 2014 03:51 PM PDT By Euan Rocha TORONTO (Reuters) - Canadian miner Sherritt International Corp on Monday urged its shareholders to back its slate of nominees for the company's board of directors over a slate put forward by activist investor George Armoyan. Sherritt filed its proxy circular on Monday, and in a letter to investors Chairman Harold Stephen assailed Armoyan as someone with no experience in Sherritt's lines of business, and said Armoyan has a poor track record on corporate governance matters and no credible new ideas for creating value beyond what management is already doing. Armoyan is chief executive of Clarke Inc, a Halifax, Nova Scotia-based investment holding company listed on the Toronto Stock Exchange. The announcement came just after Sherritt, a nickel, oil and gas producer, completed a visit with analysts and investors to its key growth project, the Ambatovy nickel mine and plant in Madagascar. Full Story | Top |
N.Y. judge lets Chevron bring fraud claims against Patton Boggs Monday, Mar 31, 2014 03:12 PM PDT | Top |
FDA panel votes in favor of two anti-infective drugs Monday, Mar 31, 2014 03:01 PM PDT By Toni Clarke WASHINGTON (Reuters) - A panel of advisers to the U.S. Food and Drug Administration gave favorable reviews on Monday to two new medications to treat acute bacterial skin infections. The panel voted unanimously that Cubist Pharmaceuticals Inc's tedizolid and Durata Therapeutics Inc's dalbavancin showed substantial evidence of safety and efficacy. The FDA is not obliged to follow the advice of its expert panels but typically does so. Cubist's shares closed up 4.4 percent at $73.15. Full Story | Top |
East Libyan rebels close to deal to reopen ports - state media Monday, Mar 31, 2014 02:10 PM PDT By Feras Bosalum and Ulf Laessing TRIPOLI (Reuters) - Rebels in eastern Libya are close to reopening three oil ports they have occupied since the summer to press Tripoli for autonomy and a greater share of oil revenue, a leader from the rebels' tribe told state media on Monday. "There are indications of an imminent breakthrough," Saleh Atawich, the top Magharba leader, said of talks with the government mediated by tribal elders, according to LANA state news agency. Atawich is from the same tribe as port rebel leader Ibrahim Jathran but also close to government thinking. Three years after the fall of Muammar Gaddafi, the oil standoff is one of the major challenges to Libya's weak central government as the blockade drains state coffers, adding to Western worries the country is sliding deeper into instability. Full Story | Top |
TSX rises on Fed remarks, posts ninth month of gains Monday, Mar 31, 2014 02:09 PM PDT | Top |
Wall Street rises on Yellen's view; S&P scores modest first quarter gain Monday, Mar 31, 2014 01:45 PM PDT | Top |
Durata's anti-infective drug shows efficacy, safety: FDA panel Monday, Mar 31, 2014 01:41 PM PDT (Reuters) - Durata Therapeutics Inc's drug to treat acute bacterial skin infections shows substantial evidence of safety and efficacy, a panel of advisers to the U.S. Food and Drug Administration concluded on Monday. The FDA is not obliged to follow the advice of its expert panels but typically does so. The intravenous drug, which would be sold under the brand name Dalvance if approved, is designed to be given in two doses, the first on day one and the second on day eight. The latest clinical trials were designed to show the drug was not inferior, in terms of efficacy, to a control arm that included vancomycin or vancomycin followed by Pfizer Inc's linezolid, which is sold under the brand Zyvox. Full Story | Top |
China summons Manila envoy over South China Sea legal case Monday, Mar 31, 2014 01:30 PM PDT By Ben Blanchard BEIJING (Reuters) - China summoned the Philippines ambassador on Monday to lodge a strong complaint over Manila's seeking of international arbitration in a festering territorial dispute over the South China Sea. The Philippines filed the case against China on Sunday at an arbitration tribunal in The Hague, subjecting Beijing to international legal scrutiny over the waters for the first time. The United States, a treaty ally of the Philippines, said on Sunday that the right of any state to use dispute resolution mechanisms under the Convention on the Law of the Sea should be respected. On Monday, the U.S. State Department accused China's coastguard of "harassment" of Philippine vessels and called its attempt on Saturday to block a Philippine resupply mission to the Second Thomas Shoal, a disputed atoll, "a provocative and destabilizing action." Chinese Deputy Foreign Minister Liu Zhenmin told the Philippines' ambassador that Beijing was "extremely dissatisfied and resolutely opposed" to the case Manila had brought to The Hague, repeating that China did not accept it and would not participate. Full Story | Top |
NHTSA chief: GM did not share critical information with U.S. agency Monday, Mar 31, 2014 01:15 PM PDT WASHINGTON (Reuters) - The head of the National Highway Traffic Safety Administration defended his agency's decision not to open a formal investigation into defective ignition switches in some General Motors cars and pointed a finger at the automaker for not sharing information with the agency. In testimony prepared for a congressional hearing on Tuesday, NHTSA acting Administrator David Friedman said: "GM had critical information that would have helped identify this defect." GM has recalled 2.6 million cars to repair a defective ignition switch that is linked to at least 13 deaths. ... Full Story | Top |
|
No comments:
Post a Comment